Journal of Vascular Surgery
Volume 45, Issue 1 , Pages 40-46 , January 2007

Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudication

  • Jonathan Golledge, MChir, MA, FRCS, FRACS

      Affiliations

    • Vascular Biology Unit, James Cook University, Townsville, Queensland, Australia
    • Townsville Hospital, Townsville, Queensland, Australia.
    • Corresponding Author InformationReprint requests: Jonathan Golledge, MChir, MA, FRCS, FRACS, The Vascular Biology Unit, James Cook University, Townsville, Queensland 4811, Australia.
    • J.G. and A.L. contributed equally to this work.
    • ,
  • Anthony Leicht, PhD

      Affiliations

    • Institute of Sport and Exercise Science, James Cook University, Townsville, Queensland, Australia
    • J.G. and A.L. contributed equally to this work.
    • ,
  • Robert G. Crowther, BSc(hons)

      Affiliations

    • Institute of Sport and Exercise Science, James Cook University, Townsville, Queensland, Australia
    • ,
  • Paula Clancy, PhD

      Affiliations

    • Vascular Biology Unit, James Cook University, Townsville, Queensland, Australia
    • ,
  • Warwick L. Spinks, PhD

      Affiliations

    • Institute of Sport and Exercise Science, James Cook University, Townsville, Queensland, Australia
    • ,
  • Francis Quigley, MS

      Affiliations

    • Townsville Hospital, Townsville, Queensland, Australia.

Received 2 August 2006 ,Accepted 1 September 2006.

References 

  1. Engstrom G, Hedblad B, Stavenow L, Jonsson S, Lind P, Janzon L, et al. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population-based cohort study. Arterioscler Thromb Vasc Biol. 2004;24:1498–1502
  2. Li TY, Rana JS, Manson JE, Willett WC, Stampfer MJ, Colditz GA, et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation. 2006;113:499–506
  3. Lorenzo C, Williams K, Hunt KJ, Haffner SM. Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care. 2006;29:625–630
  4. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. INTERHEART Study Investigators Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640–1649
  5. Rubinshtein R, Halon DA, Jaffe R, Shahla J, Lewis BS. Relation between obesity and severity of coronary artery disease in patients undergoing coronary angiography. Am J Cardiol. 2006;97:1277–1280
  6. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ. 2006;332:878–882
  7. Rana JS, Jansen AC, Zwinderman AH, Nieuwdorp M, van Aalst-Cohen ES, Jukema JW, et al. Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia. Diabetes Care. 2006;29:1125–1127
  8. Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL The SMART Study Group. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J. 2004;25:342–348
  9. Vu JD, Vu JB, Pio JR, Malik S, Franklin SS, Chen RS, et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol. 2005;96:655–658
  10. Stepp DW, Pollock DM, Frisbee JC. Low-flow vascular remodeling in the metabolic syndrome X. Am J Physiol Heart Circ Physiol. 2004;286:H964–H970
  11. Skilton MR, Moulin P, Serusclat A, Nony P, Bonnet F. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis. In press.
  12. Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K, He J. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am J Cardiol. 2005;96:1579–1583
  13. Planas A, Clara A, Pou JM, Vidal-Barraquer F, Gasol A, de Moner A, et al. Relationship of obesity distribution and peripheral arterial occlusive disease in elderly men. Int J Obes Relat Metab Disord. 2001;25:1068–1070
  14. Gorter PM, Olijhoek JK, van der Graaf Y, Algra A, Rabelink TJ, Visseren FL SMART Study Group. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis. 2004;173:363–369
  15. Alberti KG, Zimmet P, Shaw J IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059–1062
  16. Leng GC, Fowkes FG. The Edinburgh claudication questionnaire: an improved version of the WHO/Rose questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992;45:1101–1109
  17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29(Suppl 1):S43–S48
  18. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur Heart J. 2003;24:1601–1610
  19. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636–1641
  20. Norton K, Whittingham N, Carter L, Kerr D, Gore C, Marfell-Jones M. Measurement techniques in anthropometry. In:  Norton K,  Olds T editor. Anthropometrica. Sydney: UNSW Press; 2000;p. 27–75
  21. Gleeson HK, Lissett CA, Shalet SM. Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. J Clin Endocrinol Metab. 2005;90:1061–1067
  22. Golledge J, Ferguson K, Ellis M, Sabharwal T, Davies AH, Greenhalgh RM, et al. Outcome of femoropopliteal angioplasty. Ann Surg. 1999;229:146–153
  23. TASC Working Group. Management of peripheral arterial disease. Eur J Vasc Endovasc Surg. 2000;19(Suppl A):S60
  24. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc. 1991;23:402–408
  25. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295:547–553
  26. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines. Circulation. 2006;113:e463–e654
  27. Ness J, Aronow WS, Ahn C. Risk factors for symptomatic peripheral arterial disease in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 2000;48:312–314
  28. Hooi JD, Stoffers HE, Kester AD, Rinkens PE, Kaiser V, van Ree JW, et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease (The Limburg PAOD Study. Peripheral Arterial Occlusive Disease). Scand J Prim Health Care. 1998;16:177–182
  29. von Eynatten M, Schneider JG, Humpert PM, Kreuzer J, Kuecherer H, Katus HA, et al. Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol. 2006;47:2124–2126
  30. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005;111:747–753
  31. Iwashima Y, Horio T, Suzuki Y, Kihara S, Rakugi H, Kangawa K, et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis. 2006;188:384–390
  32. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106:2767–2770
  33. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol. 2006;26:224–230
  34. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 2004;314:415–419
  35. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671–674
  36. Chong PF, Garratt AM, Golledge J, Greenhalgh RM, Davies AH. The intermittent claudication questionnaire: a patient-assessed condition-specific health outcome measure. J Vasc Surg. 2002;36:764–771

 Supported by funding from the National Health and Medical Research Council (279408/379600), National Institutes of Health (R01 HL080010-01), and James Cook University.CME article

PII: S0741-5214(06)01630-2

doi: 10.1016/j.jvs.2006.09.006

Journal of Vascular Surgery
Volume 45, Issue 1 , Pages 40-46 , January 2007

Article Tools

* Image Usage & Resolution